Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

BLENREP

BELANTAMAB MAFODOTIN-BLMF

Standard Dose
70MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview BLENREP is listed in Drugs@FDA under application 761440 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BELANTAMAB MAFODOTIN-BLMF Form and strength INJECTABLE;INJECTION - 70MG Sponsor GLAXOSMITHKLINE LLC Submission history Latest submission status date: 2025-10-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview BLENREP is listed in Drugs@FDA under application 761440 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BELANTAMAB MAFODOTIN-BLMF Form and strength INJECTABLE;INJECTION - 70MG Sponsor GLAXOSMITHKLINE LLC Submission history Latest submission status date: 2025-10-23 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.